|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 |
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | |||
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. | SEC 1474 (9-02) |
1. Title of Derivative Security (Instr. 3) |
2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) |
5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) |
6. Date Exercisable and Expiration Date (Month/Day/Year) |
7. Title and Amount of Underlying Securities (Instr. 3 and 4) |
8. Price of Derivative Security (Instr. 5) |
9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) |
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) |
11. Nature of Indirect Beneficial Ownership (Instr. 4) |
||||
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||||||
Stock Appreciation Rights | $ 20.14 | 05/09/2017 | M | 3,600 | 12/31/2010 | 12/31/2017 | Common Stock | 3,600 | $ 0 | 0 | D | ||||
Stock Appreciation Rights | $ 21.57 | 05/09/2017 | M | 600 | 02/28/2011 | 02/28/2018 | Common Stock | 600 | $ 0 | 0 | D | ||||
Stock Appreciation Rights | $ 6.82 | 05/09/2017 | M | 1,840 | 02/27/2012 | 02/27/2019 | Common Stock | 1,840 | $ 0 | 0 | D | ||||
Stock Appreciation Rights | $ 22.94 | 05/09/2017 | M | 1,854 | 05/07/2013 | 05/07/2020 | Common Stock | 1,854 | $ 0 | 0 | D | ||||
Stock Appreciation Rights | $ 53.29 | 05/09/2017 | M | 2,257 | 05/18/2014 | 05/18/2021 | Common Stock | 2,257 | $ 0 | 0 | D | ||||
Stock Appreciation Rights | $ 44.79 | 05/09/2017 | M | 5,409 | 05/31/2015 | 05/31/2022 | Common Stock | 5,409 | $ 0 | 0 | D | ||||
Stock Appreciation Rights | $ 48.39 | 05/09/2017 | M | 453 | 09/01/2015 | 09/01/2022 | Common Stock | 453 | $ 0 | 0 | D | ||||
Stock Appreciation Rights | $ 30.44 | 05/09/2017 | M | 3,914 | 03/02/2017(9) | 03/02/2025 | Common Stock | 3,914 | $ 0 | 5,873 | D |
Reporting Owner Name / Address | Relationships | |||
Director | 10% Owner | Officer | Other | |
Aspauza Jossie 800 W. OYMPIC BLVD. SUITE 406 LOS ANGELES, CA 90015 |
VP, SAM/CAM |
/s/ Eileen Uy, Attorney-in-Fact for Jossie Aspauza | 05/11/2017 | |
**Signature of Reporting Person | Date |
* | If the form is filed by more than one reporting person, see Instruction 4(b)(v). |
** | Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). |
(1) | The reporting person received 1,822 shares of common stock upon the net exercise of the 3,600 stock appreciation rights ("SARS"). The reporting person forfeited 996 shares of common stock underlying the SARS in payment of the exercise price and 782 shares of common stock underlying the SARS to satisfy the withholding tax obligation resulting from the exercise, using the closing stock price on May 9, 2017 of $72.81. |
(2) | The reporting person received 295 shares of common stock upon the net exercise of the 600 SARs. The reporting person forfeited 178 shares of common stock underlying the SARS in payment of the exercise price and 127 shares of common stock underlying the SARS to satisfy the withholding tax obligation resulting from the exercise, using the closing stock price on May 9, 2017 of $72.81. |
(3) | The reporting person received 1,166 shares of common stock upon the net exercise of the 1,840 SARs. The reporting person forfeited 173 shares of common stock underlying the SARS in payment of the exercise price and 501 shares of common stock underlying the SARS to satisfy the withholding tax obligation resulting from the exercise, using the closing stock price on May 9, 2017 of $72.81. |
(4) | The reporting person received 888 shares of common stock upon the net exercise of the 1,854 SARs. The reporting person forfeited 585 shares of common stock underlying the SARS in payment of the exercise price and 381 shares of common stock underlying the SARS to satisfy the withholding tax obligation resulting from the exercise, using the closing stock price on May 9, 2017 of $72.81. |
(5) | The reporting person received 423 shares of common stock upon the net exercise of the 2,257 SARs. The reporting person forfeited 1,652 shares of common stock underlying the SARS in payment of the exercise price and 182 shares of common stock underlying the SARS to satisfy the withholding tax obligation resulting from the exercise, using the closing stock price on May 9, 2017 of $72.81. |
(6) | The reporting person received 1,456 shares of common stock upon the net exercise of the 5,409 SARs. The reporting person forfeited 3,328 shares of common stock underlying the SARS in payment of the exercise price and 625 shares of common stock underlying the SARS to satisfy the withholding tax obligation resulting from the exercise, using the closing stock price on May 9, 2017 of $72.81. |
(7) | The reporting person received 105 shares of common stock upon the net exercise of the 453 SARS. The reporting person forfeited 302 shares of common stock underlying the SARS in payment of the exercise price and 46 shares of common stock underlying the SARS to satisfy the withholding tax obligation resulting from the exercise, using the closing stock price on May 9, 2017 of $72.81. |
(8) | The reporting person received 1,592 shares of common stock upon the net exercise of the 3,914 SARs. The reporting person forfeited 1,638 shares of common stock underlying the SARS in payment of the exercise price and 684 shares of common stock underlying the SARS to satisfy the withholding tax obligation resulting from the exercise, using the closing stock price on May 9, 2017 of $72.81. |
(9) | Consists of 9,787 stock appreciation rights granted under the Herbalife Ltd. 2014 Stock Incentive Plan of which 20% vested on March 2, 2016, 20% vested on March 2, 2017, and the remaining 60% will vest on March 2, 2018. |